Evidence map›Paper›PMID 38545117›Full record

ArticleFrontiers in immunology2024

Zhichun Zhang, Yonghui Wu, Dan Shi, Chanyu Jiang, Hengyan Cao, Fengyi Jiang, Xiaomin Bao, Yan Shen, Xiao Shi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Frontiers in pharmacology · 2025
    Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zhichun Zhang *Department of Gerontology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Yonghui Wu *Graduate School of Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Dan Shi *Department of Gerontology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Chanyu JiangGraduate School of Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Hengyan CaoDepartment of Gerontology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Fengyi JiangDepartment of Gerontology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Xiaomin BaoDepartment of Gerontology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Yan ShenDepartment of Gerontology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Xiao ShiDepartment of Gerontology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Shanghai University of Traditional Chinese Medicine · CNYueyang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: To confirm the AS play efficacy in alleviating memory impairment in mice, 5×FAD transgenic mice were subjected to an open-field experiment and a novelty recognition experiment. Network pharmacology technique was used to analyze the information of key compounds and potential key targets of AS for the treatment of AD, molecular docking technique was applied to predict the binding ability of targets and compounds, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were also performed on the targets to derive the possible metabolic processes and pathway mechanisms of AS in treating AD. Quantitative real-time PCR (qRT-PCR) and western blot technique were carried out to validate the candidate genes and pathways. Results: In the open-field experiment, compared with the wild-type (WT) group, the number of times the mice in the AD group crossed the central zone was significantly reduced ( Conclusion: Our study indicates that the multi-component and multi-target properties of AS play an important role in the alleviation of anxiety and memory impairment caused by AD, and the mechanism is involved in the phosphorylation and activation of the MAPK signaling pathway. The results of this study could provide a novel perspective for the clinical treatment of AD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionEleutherococcusAnimalsMiceMolecular Docking SimulationPhosphorylationSignal TransductionAcanthopanax senticosusAlzheimer’s diseaseMAPK signaling pathwaynetwork pharmacologyneuroinflammation

Identifiers

PMID38545117
PMCPMC10965608
OpenAlexW4392757099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.